New - Biopharma Quality Control : AAV Vector Titer Determination
Biopharmaceutical quality control (QC)
AAV Vector Titer Determination
Determination of adeno-associated virus vector titer by digital PCR with MiQuant® AAV.
- Fast and easy workflow
- Quantitation independent of AAV serotype
- No DNA extraction required
- Designed for QIAcuity platform
- In-Process Control and Release Testing
- Quantiation without standard curve or further calculations
- Lyophilized kit components simplify logistics and storage
Gene therapy represents one of the most ground-breaking advancements
in modern medicine that has rapidly evolved over the last years leading
to improved methods of applications. Adeno-associated virus (AAV)
vectors are among the most prominent viral vectors for in vivo
gene therapy that target the healthy gene material to the correct
location in the organism which enables the mutated gene to be exchanged
by the healthy one.
Viral genome titer is a critical quality
attribute in AAV characterization for safe and efficacious gene therapy
products. Specificity of AAV vectors as well as the concentration of the
vector titer must be determined throughout the production process and
for final release testing.
The MiQuant® AAV kits have been developed
for the determination of AAV vector titer. Different kit versions enable
the specific detection of AAV genotype 2/6 (including genotype 1, 3
& 7) or genotype 5.
Application Areas
Determination of the AAV vector titer with the MiQuant® AAV kits is
useful at different times. During the AAV vector production process, it
can be used as an in-process control to evaluate the AAV titer. As part
of the final QC release testing the AAV titer must be determined prior
to administration to the patient. Besides these applications the
MiQuant® AAV kits can also be used for determining the AAV titer in
research and development.
Find more information on Minerva Biolabs' MiQuant® AAV in our flyer.
Products